Skip to main content
Zai Lab Limited logo

Zai Lab Limited — Investor Relations & Filings

Ticker · 9688 ISIN · KYG9887T1168 LEI · 549300P2UYQ9U5LY1T58 HKEX Manufacturing
Open in API
Filings indexed 388 across all filing types
Latest filing 2025-01-06 Regulatory Filings
Country KY Cayman Islands
Listing HKEX 9688

About Zai Lab Limited

http://www.zailaboratory.com

Zai Lab Limited is an innovative, research-based, commercial-stage biopharmaceutical company dedicated to discovering, developing, and commercializing transformative therapies that address medical conditions with significant unmet needs. The company focuses its pipeline and development efforts across four core therapeutic areas: oncology, immunology, neuroscience, and infectious disease. Zai Lab employs a strategy of internal research and global partnerships to advance best-in-class and first-in-class medicines. A key commercial product is ZEJULA (niraparib), utilized as a maintenance treatment for ovarian cancer in markets including mainland China.

Recent filings

Filing Released Lang Actions
OVERSEAS REGULATORY ANNOUNCEMENT - FORM 8-K
Regulatory Filings Classification · 85% confidence The document is an “Overseas Regulatory Announcement – Form 8-K” filed by Zai Lab Limited. It repeatedly references the U.S. SEC Form 8-K and provides the full text of that current report, including Items 1.01, Item 2.03, and Item 9.01, plus attached exhibits. There is no sign this is merely a brief notice of an upcoming report (it contains the full report), nor does it fit into any specific category such as earnings release or annual report. As a U.S. SEC filing type not covered by other specific categories, it falls under the general Regulatory Filings category (RNS).
2025-01-06 English
LIST OF DIRECTORS AND THEIR ROLES AND FUNCTIONS
Board/Management Information Classification · 87% confidence The document is a Hong Kong Exchange announcement titled “LIST OF DIRECTORS AND THEIR ROLES AND FUNCTIONS,” listing the company’s board members, their positions, and committee memberships. This is not a full report like an Annual Report or Interim Report, nor is it an earnings release or proxy solicitation; it is a clear Board/Management Information notice. Therefore, it should be classified under the Board/Management Information category (MANG).
2024-12-31 English
RESIGNATION OF INDEPENDENT NON-EXECUTIVE DIRECTOR
Board/Management Information Classification · 95% confidence The document is a corporate announcement from Zai Lab Limited regarding the resignation of an independent non-executive director, Dr. Kai-Xian Chen, effective December 31, 2024. This pertains to a change in the company’s board composition. This matches the definition of “Board/Management Information” (MANG).
2024-12-31 English
Next Day Disclosure Return
Share Issue/Capital Change Classification · 94% confidence The document is a Hong Kong Stock Exchange “Next Day Disclosure Return” (Form FF305) for an equity issuer, Zai Lab Limited, reporting changes in issued shares – specifically the issue of 8,000,000 new ordinary shares under its equity incentive plans. This is not a full annual or interim report, nor an earnings release; rather it is a regulatory announcement of a share issue/capital change. It therefore falls under Share Issue/Capital Change (SHA).
2024-12-17 English
Monthly Return of Equity Issuer on Movements in Securities for the month ended 30 November 2024
Regulatory Filings Classification · 90% confidence The document is titled "Monthly Return for Equity Issuer and Hong Kong Depositary Receipts listed under Chapter 19B of the Exchange Listing Rules" (Form FF301). It is a standardized exchange filing showing monthly movements in share capital, issued shares, share options, RSUs, treasury shares, and confirmations pursuant to the HKEX Listing Rules. This is not an annual or interim financial report, nor a management or earnings release. It is a regulatory submission required by the exchange. Therefore, it falls into the "Regulatory Filings" fallback category.
2024-12-05 English
GRANT OF RESTRICTED SHARE UNITS
Share Issue/Capital Change Classification · 85% confidence The document is an official regulatory announcement under the HKEX Listing Rules (Rules 17.06A/B/C) disclosing the grant of restricted share units (RSUs) under the Company’s 2024 Equity Incentive Plan. It details the number of RSUs granted, underlying shares, vesting schedule and grant date. This is not an earnings release, management discussion, or director dealing notice, nor is it a proxy statement or ESG report. It constitutes a corporate action involving the issuance of equity under an incentive plan. Hence, it should be classified as a Share Issue/Capital Change (SHA).
2024-12-03 English

Browse filings by year

7 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.